Product/Composition:- | Liposomal Amphotericin B Injectable |
---|---|
Strength:- | 50 mg/vial |
Form:- | Injection |
Reference Brands:- | AmBisome(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Liposomal Amphotericin B binds to fungal ergosterol, creating pores that disrupt cell membrane integrity and cause fungal cell death. It offers broad-spectrum activity, enhanced tissue penetration, and reduced toxicity compared to conventional formulations. Benefits include effective treatment of severe systemic infections with fewer side effects, improving patient outcomes.
Liposomal Amphotericin B is approved in the EU and US for severe fungal infections. In the EU, Gilead’s AmBisome is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, FDA-approved AmBisome is backed by comprehensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and submissions, visit PharmaTradz. We facilitate efficient market access for Liposomal Amphotericin B, ensuring adherence to European and American standards for safe, effective antifungal therapy, reducing toxicity while maintaining efficacy in severe infections.